Names and pronunciation
(riff′ah-pen-teen) Priftin
Source page 1156
Loading InternPractice…
Individual generic drug information
Extracted information for rifapentine only.
(riff′ah-pen-teen) Priftin
Source page 1156
Func. class.: Antitubercular
Source page 1156
Chem. class.: Rifamycin derivative
Source page 1156
Do not confuse: rifapentine/rifAMPin/rifabutin
Source page 1156
ACTION: Inhibits DNA-dependent polymerase, decreases tubercle bacilli replication
Source page 1156
USES: Pulmonary TB; must be used with at least one other antitubercular agent
Source page 1156
Extracted information for rifapentine only.
CONTRAINDICATIONS: Hyper sensitivity to rifamycins, porphyria Precautions: Pregnancy, breastfeeding, children <12 yr, geriatric patients, hepatic disease, blood dyscrasias, HIV
Source page 1156
SIDE EFFECTS CNS: Headache, fatigue, anxiety, dizziness EENT: Visual disturbances GI: Nausea, vomiting, anorexia, diar- rhea, bilirubinemia, hepatitis, increased ALT, AST, heartburn, pancreatitis, CDAD GU: Hematuria, pyuria, proteinuria, uri- nary casts, urine discoloration HEMA: Thrombocytopenia, leukopenia, neutropenia, lymphopenia, anemia, leu- kocytosis, purpura, hematoma INTEG: Rash, pruritus, urticaria, acne MISC: Increased B/P MS: Gout, arthrosis
Source page 1156
INTERACTIONS • Do not use with protease inhibitors Decrease: action of amitriptyline, anti- coagulants, antidiabetics, barbiturates, β-blockers, chloramphenicol, clar- ithromycin, clofibrate, corticosteroids, cycloSPORINE, dapsone, delavirdine, diazePAM, digoxin, diltiaZEM, diso- pyramide, doxycycline, fentaNYL, flu- conazole, haloperidol, indinavir, itra- conazole, ketoconazole, methadone, mexiletine, nelfinavir, NIFEdipine, nor- triptyline, oral contraceptives, pheno- thiazines, phenytoin, progestins, quiNI- Dine, quiNINE, ritonavir, saquinavir, sildenafil, tacrolimus, theophylline, thyroid preparations, tocainide, vera- pamil, warfarin, zidovudine Drug/Food Increase: absorption with food Drug/Lab Test Increase: LFTs, platelets Decrease: HB, WBC Interference: folate level, vit B12
Source pages 1156, 1157
Extracted information for rifapentine only.
DOSAGE AND ROUTES Intensive phase • Adult/adolescent >12 yr: PO 600 mg (four 150-mg tabs) 2×/wk with an inter- val of 72 hr between doses × 2 mo; must be given with at least 1 other antitubercu- lar agent Continuation phase • Adult/adolescent >12 yr: PO 600 mg weekly × 4 mo in combination with iso- niazid or other appropriate antitubercu- lar product
Source page 1156
Available forms: Tabs 150 mg
Source page 1156
Administer: • May give with food for GI upset; use other products for TB • Antiemetic if vomiting occurs • After C&S completed; monthly to de- tect resistance
Source page 1156
Extracted information for rifapentine only.
Assess: • Baselines of CBC, AST, ALT, bilirubin, platelets • Infection: sputum culture, lung sounds • Signs of anemia: Hct, HB, fatigue • Hepatic studies monthly: ALT, AST, bili- rubin; decreased appetite, jaundice, dark urine, fatigue • Renal status monthly: BUN, creatinine, output, specific gravity, urinalysis • CDAD: diarrhea, fever, abdominal pain/ cramping, bloody diarrhea; discontinue if present, notify prescriber
Source page 1157
Evaluate: • Therapeutic response: decreased symptoms of TB, culture negative
Source page 1157
CLINICAL CONSIDERATIONS
Source page 1157
Patient and caregiver information: • That compliance with dosage sched- ule, duration necessary • That scheduled appointments must be kept because relapse may occur • That urine, feces, saliva, sputum, sweat, tears may be colored red-orange; that soft contact lenses, dentures may be permanently stained • To report flulike symptoms: excessive fatigue, anorexia, vomiting, sore throat; unusual bleeding, yellowish discoloration of skin, eyes; diarrhea with pus, mucus, blood • Pregnancy/breastfeeding: to use al- ternative method of contraception; that oral contraceptive action may be de- creased; to notify prescriber if pregnancy is planned, suspected; to avoid breast- feeding
Source page 1157
Extracted information for rifapentine only.
PHARMACOKINETICS Peak 5-6 hr; half-life 13 hr; metabo- lized in liver (active/inactive metabo- lites); excreted in urine, feces, breast milk; protein binding 97%; steady-state 10 days; CYP450 3A4, 2C8/9 inducer
Source page 1156
Filter the extracted dose blocks for this individual drug.
Intensive phase
• Adult/adolescent >12 yr: PO 600 mg (four 150-mg tabs) 2×/wk with an inter- val of 72 hr between doses × 2 mo; must be given with at least 1 other antitubercu- lar agent Continuation phase
Candidate age grouping · source page 1156
Intensive phase
• Adult/adolescent >12 yr: PO 600 mg weekly × 4 mo in combination with iso- niazid or other appropriate antitubercu- lar product
Candidate age grouping · source page 1156